Chemkart India IPO Listing: Shares Gain 4.44% on Debut After Strong Investor Response

Chemkart India IPO Listing: Sluggish Debut with Subdued Gains, Shares Close Up 4.44% on Listing Day

Mumbai, July 14, 2025 – Chemkart India Limited, a prominent distributor of specialty food and health ingredients, made its stock market debut on the BSE SME platform today.

Despite strong interest from institutional investors during the IPO phase, the listing saw only a modest gain at the open.

Shares of the company opened at ₹250.00 apiece against the issue price of ₹248.00, marking a minimal listing premium of 0.81%.

Though the initial reaction was muted, the stock showed resilience throughout the day. It touched an intraday high of ₹262.00 and eventually settled at ₹259.00 by the close of trading, delivering a day-one return of 4.44% for investors who were allotted shares in the IPO.

IPO Overview: Solid Subscription Despite Conservative Listing

Chemkart India’s IPO was open for subscription between July 7 and July 9, 2025. The company aimed to raise ₹80.08 crore through a combination of fresh equity issuance and an Offer for Sale (OFS). The IPO was priced at ₹248 per share, and the lot size for retail investors was 600 shares.

Investor demand was strong, particularly among institutional participants. Here’s how the IPO was subscribed:

• Qualified Institutional Buyers (QIBs): 13.69 times
• Non-Institutional Investors (NIIs): 5.64 times
• Retail Individual Investors (RIIs): 1.63 times
• Overall Subscription: 5.91 times

The strong response, especially from QIBs, indicated investor confidence in the company’s business model, growth potential, and financial performance.

However, the lackluster listing suggests that near-term sentiment may have been tempered by broader market volatility or valuation concerns.

IPO Structure: Fresh Issue and Offer for Sale

The ₹80.08 crore raised through the IPO includes both a fresh issue of shares and an Offer for Sale (OFS):

• Fresh Issue: The company issued new shares to raise capital for business expansion and debt repayment.
• Offer for Sale (OFS): A total of 6,29,200 equity shares worth ₹15.60 crore were sold by existing shareholders. The proceeds from the OFS have gone to the selling stakeholders, not the company.

This dual structure allowed Chemkart India to secure funding for its operational goals while also providing an exit opportunity to early investors.

Utilization of IPO Proceeds

Chemkart India has laid out a clear plan for deploying the capital raised through the fresh issue. The key allocations are as follows:

• ₹34.68 crore will be used to establish a manufacturing facility through its wholly-owned subsidiary, Easy Raw Materials Private Limited. This move will help the company transition from being solely a distributor to a manufacturer, potentially improving profit margins and enhancing control over product quality and supply chains.
• ₹20.00 crore is earmarked for debt repayment, which will help reduce the company’s financial leverage and improve its balance sheet health.
• The remaining funds will be used for general corporate purposes, including brand building, working capital needs, and exploring strategic partnerships or product development.

This forward-looking capital allocation indicates Chemkart’s intent to strengthen its operations, enhance profitability, and support long-term growth.

Company Background: Chemkart India at a Glance

Founded in 2015, Chemkart India Limited operates in the high-growth segment of food, nutraceutical, and health ingredients.

The company has built a strong presence as a distributor of premium quality ingredients and caters to a diverse clientele across the pharmaceutical, dietary supplement, and functional food industries.

Its broad product portfolio includes:

• Amino acids
• Vitamins and minerals
• Proteins and peptides
• Herbal extracts
• Sports nutrition ingredients
• Nucleotides and enzymes
• Other specialty food additives

With a focus on quality, innovation, and customer-centric solutions, Chemkart has established a reliable supplier network across global markets and continues to expand its product reach within India.

Financial Performance: Strong and Consistent Growth

Chemkart India has demonstrated impressive financial growth in recent years. Its revenue and profitability have both shown a healthy upward trajectory:

• FY 2023: Net profit stood at ₹7.66 crore
• FY 2024: Net profit nearly doubled to ₹14.52 crore
• FY 2025: Net profit surged to ₹24.26 crore

This represents a compound annual growth rate (CAGR) of over 70% in net profits over two years. In terms of revenue, the company grew at a CAGR of more than 24%, reaching ₹205.46 crore in FY25. Such financial metrics reflect robust demand, operational efficiency, and effective cost management.

The company’s growth is also driven by rising demand for health supplements, wellness products, and functional foods — trends that are expected to accelerate in the coming years, both globally and in India.

Market Outlook and Investment Perspective

Although Chemkart India’s IPO listing gains were modest, the post-listing upward movement suggests investor confidence in the company’s fundamentals.

The health and wellness industry is undergoing a significant transformation, with increasing consumer awareness and rising demand for nutritional supplements — trends that play to Chemkart’s strengths.

The company’s upcoming manufacturing expansion is expected to improve its cost structure and margins.

Additionally, debt reduction and operational scalability could position Chemkart as a serious player in the ingredients manufacturing space, beyond distribution.

However, investors should also consider potential risks, including raw material price volatility, regulatory changes in the nutraceutical space, and competition from domestic and global players.

Final Thoughts

Chemkart India’s stock market debut may have lacked the fireworks seen in some other SME IPOs, but the company’s fundamentals and strong subscription response suggest a positive long-term outlook.

With clear growth plans, solid financial performance, and a presence in a fast-expanding industry, Chemkart India appears well-positioned for sustainable value creation.

Investors looking for exposure to India’s booming health and wellness sector may find Chemkart an interesting mid-to-long-term opportunity, especially as it transitions into manufacturing and expands its footprint.